• ITGA2B (heavy chain, Cleaved-Leu32) rabbit pAb
1 1

Upingbio

YP-Ab-16819-100UL

ITGA2B (heavy chain, Cleaved-Leu32) rabbit pAb

ITGA2B (heavy chain, Cleaved-Leu32) rabbit pAb

$0.00 USD
$0.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
  • Gene Name: ITGA2B GP2B ITGAB
  • Immunogen: Synthesized peptide derived from human ITGA2B (heavy chain, Cleaved-Leu32)
  • Specificity: This antibody detects endogenous levels of Human ITGA2B (heavy chain, Cleaved-Leu32, protein was cleaved amino acid sequence between 31-32 )
  • Composition: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
  • Source: Polyclonal, Rabbit,IgG
  • Dilution ratio: WB 1:500-2000;IHC-p 1:50-300
  • Purification process: The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
  • Concentration: 1 mg/ml
  • Storage: -20°C/1 year
  • Other Names: Integrin alpha-IIb (GPalpha IIb;GPIIb;Platelet membrane glycoprotein IIb;CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb light chain, form 2]
  • Background: This gene encodes a member of the integrin alpha chain family of proteins. The encoded preproprotein is proteolytically processed to generate light and heavy chains that associate through disulfide linkages to form a subunit of the alpha-IIb/beta-3 integrin cell adhesion receptor. This receptor plays a crucial role in the blood coagulation system, by mediating platelet aggregation. Mutations in this gene are associated with platelet-type bleeding disorders, which are characterized by a failure of platelet aggregation, including Glanzmann thrombasthenia. [provided by RefSeq, Jan 2016],
  • Function: disease:Defects in ITGA2B are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. This autosomal recessive disorder is the most common inherited disease of platelets. GT is characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors.,fun
  • Species: Human;Rat;Mouse;
  • Range: WB;IHC
  • Protein: ITGA2B (heavy chain, Cleaved-Leu32)
  • DA: 95 110kD
View full details